AP3436A - Use of ammonium chloride in therapy - Google Patents

Use of ammonium chloride in therapy

Info

Publication number
AP3436A
AP3436A AP2011005798A AP2011005798A AP3436A AP 3436 A AP3436 A AP 3436A AP 2011005798 A AP2011005798 A AP 2011005798A AP 2011005798 A AP2011005798 A AP 2011005798A AP 3436 A AP3436 A AP 3436A
Authority
AP
ARIPO
Prior art keywords
therapy
ammonium chloride
ammonium
chloride
Prior art date
Application number
AP2011005798A
Other languages
English (en)
Other versions
AP2011005798A0 (en
Inventor
Alessandro Gagnoni
Diamantis Kiassos
Original Assignee
Rainbow Pharmaceutical Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rainbow Pharmaceutical Sa filed Critical Rainbow Pharmaceutical Sa
Publication of AP2011005798A0 publication Critical patent/AP2011005798A0/xx
Application granted granted Critical
Publication of AP3436A publication Critical patent/AP3436A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2011005798A 2009-01-02 2009-12-29 Use of ammonium chloride in therapy AP3436A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/348,220 US8840934B2 (en) 2009-01-02 2009-01-02 Uses of ammonium chloride
PCT/EP2009/067993 WO2010076323A1 (en) 2009-01-02 2009-12-29 Use of ammonium chloride in therapy

Publications (2)

Publication Number Publication Date
AP2011005798A0 AP2011005798A0 (en) 2011-08-31
AP3436A true AP3436A (en) 2015-10-31

Family

ID=41649998

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005798A AP3436A (en) 2009-01-02 2009-12-29 Use of ammonium chloride in therapy

Country Status (15)

Country Link
US (1) US8840934B2 (pt)
EP (1) EP2373320A1 (pt)
JP (1) JP2012514583A (pt)
KR (1) KR20110101125A (pt)
CN (1) CN102209549A (pt)
AP (1) AP3436A (pt)
AU (1) AU2009334784B2 (pt)
BR (1) BRPI0923886A2 (pt)
CA (1) CA2740521A1 (pt)
EA (1) EA024723B1 (pt)
IL (1) IL212208A0 (pt)
MX (1) MX2011004189A (pt)
NZ (1) NZ592077A (pt)
WO (1) WO2010076323A1 (pt)
ZA (1) ZA201102416B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095833A2 (en) * 1982-05-03 1983-12-07 Roland Vilagines Method of preventing infection by viropexis-penetrating viruses
WO1996032952A1 (en) * 1995-04-21 1996-10-24 Oswald Edmonds Hooper Caffeine composition as medicament and use thereof
MX9503783A (es) * 1995-09-04 1997-03-29 William C Stacey Combinaciones de compuestos de cloruro de amonio para el tratamiento de infecciones virales.
EP1875918A2 (en) * 2006-07-03 2008-01-09 KIASSOS, Diamantis New use of ammonium chloride for the therapy of total or partial hepatic failure and necrosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
US4346082A (en) * 1980-01-04 1982-08-24 The Vinoxen Company Method of employing therapeutic composition comprising ammonium or substituted ammonium compounds for treatment of alcoholism
NL8401782A (nl) 1984-06-04 1986-01-02 Jan Willem Bins Therapeutisch preparaat met ammoniumnitraat als werkzame stof.
NZ231236A (en) 1988-11-11 1992-07-28 Manrex Australia Pty Ltd Assembly for blister package
AU642173B2 (en) * 1989-11-08 1993-10-14 Oswald Edmonds Hooper Improvements in or relating to a treatment and or a method of treating
US5275828A (en) * 1989-11-08 1994-01-04 Hooper Oswald E Treatment and/or a method of treating equine viral and bacterial infections
JPH0789862A (ja) * 1990-05-29 1995-04-04 Toyobo Co Ltd 抗炎症性、免疫抑制性および鎮痛性組成物、およびこれらの組成物を用いた自己免疫疾患の治療方法
SE9200502D0 (sv) 1992-02-20 1992-02-20 Astra Ab Novel antioxidants
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
GR1003980B (el) 2001-04-20 2002-09-03 Ιωαννου Διαμαντης Κιασσος Νεα χρηση του χλωριουχου αμμωνιου για τη θεραπεια των ενδοηπατικων χολοστασεων οφειλομενων εις δυσπραγια του ηπατικου κυτταρου
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
GR20020100405A (el) 2002-09-12 2004-05-24 Διαμαντης Ιωαννου Κιασσος Νεα χρηση του nh4 cl για την θεραπεια της ηπατικης ινωσεως νεκρωσεως και εγκεφαλοπαθιας οξειας και χρονιας ηπατικης ανεπαρκειας. νεα χρηση του nh4 cl για την θεραπεια της υπερχολερυθριναιμιας, υπερτρασανεμιας προκιρρωτικων και κιρρωτικων καταστασεων του ηπατος, ως επισης για την προληψη της μετατροπης των ως ανω νοσηματων εις νεοπλασματα του ηπατος.
ES2703874T3 (es) 2004-08-23 2019-03-12 Pejo Iserlohn Heilmittel Und Diaet Gmbh & Co Kg Psicoestimulante que contiene una composición farmacéutica
US20070015839A1 (en) 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20070251852A1 (en) * 2006-04-28 2007-11-01 David Purdy Multiple medication package

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0095833A2 (en) * 1982-05-03 1983-12-07 Roland Vilagines Method of preventing infection by viropexis-penetrating viruses
WO1996032952A1 (en) * 1995-04-21 1996-10-24 Oswald Edmonds Hooper Caffeine composition as medicament and use thereof
MX9503783A (es) * 1995-09-04 1997-03-29 William C Stacey Combinaciones de compuestos de cloruro de amonio para el tratamiento de infecciones virales.
EP1875918A2 (en) * 2006-07-03 2008-01-09 KIASSOS, Diamantis New use of ammonium chloride for the therapy of total or partial hepatic failure and necrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUPERTI F ET AL: "THE EFFECT OF LIPOPHILIC AMINES ON THE GROWTH OF HEPATITIS A VIRUS IN FRP-3 CELLS" ARCHIVES OF VIROLOGY, SPRINGER WIEN, AT, vol. 96, no. 3-4, 1 January 1987 (1987-01-01), pages 289-296 *
WAN YUNG SHIN ET AL: "AMMONIUM CHLORIDE TOLERANCE TESTS IN RABBITS INTRAVENOUSELY ADMINISTERED WITH MULTIPLE DOSES OF CARBON TETRACHLORIDE" GORYE DAIHAN-YO JABJI - KOREA UNIVERSITY MEDICAL JOURNAL, KORYO TAEHAKKYO UIGWA TACHAK, SEOUL, KR, vol. 9, no. 1, 1 January 1972 (1972-01-01) , pages 113-123 *

Also Published As

Publication number Publication date
EA024723B1 (ru) 2016-10-31
IL212208A0 (en) 2011-06-30
MX2011004189A (es) 2011-08-12
JP2012514583A (ja) 2012-06-28
NZ592077A (en) 2013-05-31
US8840934B2 (en) 2014-09-23
CA2740521A1 (en) 2010-07-08
AU2009334784B2 (en) 2014-01-16
EA201101036A1 (ru) 2012-01-30
EP2373320A1 (en) 2011-10-12
AU2009334784A1 (en) 2010-07-08
ZA201102416B (en) 2012-06-27
CN102209549A (zh) 2011-10-05
KR20110101125A (ko) 2011-09-15
AP2011005798A0 (en) 2011-08-31
WO2010076323A1 (en) 2010-07-08
BRPI0923886A2 (pt) 2015-07-28
US20100173020A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
HK1173654A1 (zh) 治療化合物及相關的使用方法
ZA201209484B (en) Skin antiaging treatment
GB201120993D0 (en) Novel compounds and their use in therapy
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
EP2817304A4 (en) NOVEL COMPOUNDS AND THEIR THERAPEUTIC USE
GB201011411D0 (en) Therapeutic compounds and their use
IL212208A0 (en) Use of ammonium chloride in therapy
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
EP2578215A4 (en) USE OF OXALOACETATE FOR THE TREATMENT OF ISCHEMIA
HK1182397A1 (en) New octapeptide compounds and their use in therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
IL222870A0 (en) Use of ccl1 in therapy
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
HU1000623D0 (en) Thiocyanate for use in smoking cessation therapy
GB0913300D0 (en) Therapeutic compounds and their use
EP2504347A4 (en) AMPLIFICATION OF THE THERAPEUTIC EFFECT OF ACUPUNCTURE BY ADENOSINE
GB201102208D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy
GB201102212D0 (en) Inventions and therapy